Search

Your search keyword '"Cicchetti F"' showing total 306 results
Start Over Author "Cicchetti F"
306 results on '"Cicchetti F"'

7. Ms−275 (Entinostat) promotes radio-sensitivity in pax3-foxo1 rhabdomyosarcoma cells

Author

Cassandri, M., Pomella, S., Rossetti, A., Petragnano, F., Milazzo, L., Vulcano, F., Camero, S., Codenotti, S., Cicchetti, F., Maggio, R., Festuccia, C., Gravina, G. L., Fanzani, A., Megiorni, F., Catanoso, M., Marchese, C., Tombolini, V., Locatelli, Franco, Rota, R., Marampon, F., Locatelli F. (ORCID:0000-0002-7976-3654), Cassandri, M., Pomella, S., Rossetti, A., Petragnano, F., Milazzo, L., Vulcano, F., Camero, S., Codenotti, S., Cicchetti, F., Maggio, R., Festuccia, C., Gravina, G. L., Fanzani, A., Megiorni, F., Catanoso, M., Marchese, C., Tombolini, V., Locatelli, Franco, Rota, R., Marampon, F., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. About 25% of RMS expresses fusion oncoproteins such as PAX3/PAX7-FOXO1 (fusion-positive, FP) while fusion-negative (FN)-RMS harbors RAS mutations. Radiotherapy (RT) plays a crucial role in local control but metastatic RMS is often radio-resistant. HDAC inhibitors (HDACi) radio-sensitize different cancer cells types. Thus, we evaluated MS−275 (Entinostat), a Class I and IV HDACi, in combination with RT on RMS cells in vitro and in vivo. MS−275 reversibly hampered cell survival in vitro in FN-RMS RD (RASmut) and irreversibly in FP-RMS RH30 cell lines down-regulating cyclin A, B, and D1, up-regulating p21 and p27 and reducing ERKs activity, and c-Myc expression in RD and PI3K/Akt/mTOR activity and N-Myc expression in RH30 cells. Further, MS−275 and RT combination reduced colony formation ability of RH30 cells. In both cell lines, co-treatment increased DNA damage repair inhibition and reactive oxygen species formation, down-regulated NRF2, SOD, CAT and GPx4 anti-oxidant genes and improved RT ability to induce G2 growth arrest. MS−275 inhibited in vivo growth of RH30 cells and completely prevented the growth of RTunresponsive RH30 xenografts when combined with radiation. Thus, MS−275 could be considered as a radio-sensitizing agent for the treatment of intrinsically radio-resistant PAX3-FOXO1 RMS.

Published
2021

18. Outcome of cell suspension allografts in a patient with\ud Huntington’s disease

Author

Maxan, A., Mason, S., Saint-Pierre, M., Smith, E., Ho, Aileen, Harrower, T., Watts, C., Tai, Y., Pavese, N., Savage, J. C., Tremblay, M-E, Gould, P., Rosser, A. E., Dunnett, S. B., Piccini, P, Barker, R. A., and Cicchetti, F.

Subjects
surgical procedures, operative
Abstract

For patients with incurable neurodegenerative disorders\ud such as Huntington’s (HD) and Parkinson’s disease,\ud cell transplantation has been explored as a potential\ud treatment option. Here, we present the first clinicopathological study of a patient with HD in receipt of\ud cell-suspension striatal allografts who took part in the\ud NEST-UK multicenter clinical transplantation trial. Using\ud various immunohistochemical techniques, we found a\ud discrepancy in the survival of grafted projection neurons\ud with respect to grafted interneurons as well as\ud major ongoing inflammatory and immune responses to\ud the grafted tissue with evidence of mutant huntingtin\ud aggregates within the transplant area. Our results indicate\ud that grafts can survive more than a decade posttransplantation,\ud but show compromised survival with\ud inflammation and mutant protein being observed\ud within the transplant site.

Published
2018

22. GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington’s disease: involvement of astrocyte–neuron interactions

Author

L'Episcopo, F, primary, Drouin-Ouellet, J, additional, Tirolo, C, additional, Pulvirenti, A, additional, Giugno, R, additional, Testa, N, additional, Caniglia, S, additional, Serapide, M F, additional, Cisbani, G, additional, Barker, R A, additional, Cicchetti, F, additional, and Marchetti, B, additional

Published
2016
Full Text
View/download PDF

23. Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.

Author

Cisbani, G, Drouin-Ouellet, Janelle, Gibrat, C, Saint-Pierre, M, Lagacé, M, Badrinarayanan, S, Lavallée-Bourget, M H, Charest, J, Chabrat, A, Boivin, L, Lebel, M, Bousquet, M, Lévesque, M, Cicchetti, F, Cisbani, G, Drouin-Ouellet, Janelle, Gibrat, C, Saint-Pierre, M, Lagacé, M, Badrinarayanan, S, Lavallée-Bourget, M H, Charest, J, Chabrat, A, Boivin, L, Lebel, M, Bousquet, M, Lévesque, M, and Cicchetti, F

Abstract

The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing.

Published
2015

25. Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease

Author

Cisbani, G., primary, Drouin-Ouellet, J., additional, Gibrat, C., additional, Saint-Pierre, M., additional, Lagacé, M., additional, Badrinarayanan, S., additional, Lavallée-Bourget, M.H., additional, Charest, J., additional, Chabrat, A., additional, Boivin, L., additional, Lebel, M., additional, Bousquet, M., additional, Lévesque, M., additional, and Cicchetti, F., additional

Published
2015
Full Text
View/download PDF

31. Total androgenic blockade: Results obtained by the Objective National Prostatic Carcinoma Project

Author

Martorana, G., Oneto, F., Giuliani, L., Boccardo, F., Guarneri, D., Decensi, A., Rubagotti, A., Selvaggi, F. P., Delli Ponti, U. , Cortellini, P. , Bruttini, G. P. , Epis, R. , Comeri, G. , Gallo, G. , Ferraris, Borin, D., Carbone, G., Cicchetti, F., BELGRANO, Emanuele, Martorana, G., Oneto, F., Giuliani, L., Boccardo, F., Guarneri, D., Decensi, A., Rubagotti, A., Selvaggi, F. P., Delli, Ponti, U., Cortellini, P., Bruttini, G. P., Epi, R., Comeri, G., Gallo, G., Ferrari, Belgrano, Emanuele, Borin, D., Carbone, G., and Cicchetti, F.

Subjects
goserelin, flutamide
Published
1992

Catalog

Books, media, physical & digital resources
See catalog results